Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Simultaneous HCV and HIV-1 Prime-Boost Vaccines in Healthy Volunteers
NCT02362217Phase 1Completed
- Sponsor
- University of Oxford
- Start
- Oct 2014
- Primary completion
- Aug 2016
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of AdCh3NSmut, MVA-NSmut, ChAdV63.HIVconsv and MVA.HIVconsv in hepatitis C (HCV) and human immunodeficiency virus infection (HIV) (3 arms), sponsored by University of Oxford. Primary endpoint: Proportion of volunteers who develop a grade 3 or 4 local or systemic reaction. Started Oct 2014; status: completed.
02
Drugs
AdCh3NSmutMVA-NSmutChAdV63.HIVconsvMVA.HIVconsv
03
Conditions
hepatitis C (HCV)human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02362217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02362217.